NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBYGet Rating) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the stock.

Shares of NBY opened at $0.18 on Friday. The company’s fifty day moving average price is $0.27. The firm has a market capitalization of $9.38 million, a P/E ratio of -1.22 and a beta of 3.29. NovaBay Pharmaceuticals has a 1 year low of $0.17 and a 1 year high of $0.88.

NovaBay Pharmaceuticals (NYSE:NBYGet Rating) last posted its earnings results on Tuesday, March 29th. The company reported ($0.02) EPS for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 56.76% and a negative net margin of 69.17%. The firm had revenue of $2.64 million during the quarter. As a group, equities analysts forecast that NovaBay Pharmaceuticals will post -0.08 earnings per share for the current fiscal year.

NovaBay Pharmaceuticals Company Profile (Get Rating)

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.

Read More

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.